Opdualag 240 mg/80 mg concentrate for solution for infusion
*Company:
Bristol-Myers Squibb Pharma EEIGStatus:
No Recent UpdateLegal Category:
Product subject to restricted prescription (C)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
File name
1425-GB-2500014 Opdualag UK+IRE Patient Card_v4_WM.pdf
Reasons for updating
- Replace File
File name
1425-GB-2500017 Ireland Opdualag HCP Letter_v4-SIGNED.pdf
Reasons for updating
- Add New Doc
File name
1425-GB-2500014 Opdualag UK+IRE Patient Card_v4_WM.pdf
Reasons for updating
- Add New Doc
Updated on 01 August 2025
File name
opdualag-pil-17Jul2025.pdf
Reasons for updating
- New PIL for new product
Updated on 01 August 2025
File name
opdualag-smpc-17Jul2025.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to restricted prescription (C)
Bristol-Myers Squibb Pharma EEIG
Address:
Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, D15 T867, IrelandMedical Information E-mail:
medical.information@bms.comTelephone:
+353 1 483 3625Medical Information Direct Line:
Freephone 1 800 749 749Stock Availability:
bmscustomer-service.chester@bms.com